PD-L1 expression in tumor metastasis is different between uveal melanoma and cutaneous melanoma

Immunotherapy. 2017 Dec;9(16):1323-1330. doi: 10.2217/imt-2017-0066.

Abstract

Aim: To compare PD-L1 expression between metastatic uveal melanoma (MUM) and metastatic cutaneous melanoma (MCM).

Materials & methods: A total of 295 MCM and 78 MUM specimens were analyzed for tumor cell PD-L1 expression. Additionally, 91 MCM and 45 MUM specimens were analyzed for PD-1 expression on tumor-infiltrating lymphocytes.

Results: A total of 77/295 (26.1%) MCM specimens expressed PD-L1 as compared to 4/78 (5.1%) MUM specimens (p < 0.0001). PD-1 expression on tumor-infiltrating lymphocytes was greater in MCM (73.6%; 67/91) than in MUM (51.1%; 23/45), respectively (p = 0.009).

Conclusion: Significant differences exist in PD-L1 expression between MCM and MUM. The lower PD-L1 expression in MUM may provide a rationale for failure of PD-1 inhibitor therapy and suggests that immune evasion in this disease may occur via alternative mechanisms.

Publication types

  • Comparative Study

MeSH terms

  • Antibodies, Monoclonal / therapeutic use*
  • B7-H1 Antigen / immunology*
  • Diagnosis, Differential
  • Gene Expression Regulation
  • Humans
  • Immunotherapy / methods*
  • Lymphocytes, Tumor-Infiltrating / physiology*
  • Melanoma / diagnosis
  • Melanoma / metabolism*
  • Melanoma / therapy
  • Neoplasm Metastasis
  • Prognosis
  • Skin Neoplasms / diagnosis
  • Skin Neoplasms / metabolism*
  • Skin Neoplasms / therapy
  • Treatment Outcome
  • Tumor Escape
  • Uveal Melanoma
  • Uveal Neoplasms / diagnosis
  • Uveal Neoplasms / metabolism*
  • Uveal Neoplasms / therapy

Substances

  • Antibodies, Monoclonal
  • B7-H1 Antigen